dorsaVi v6.5 Sensor Advances Physical AI Strategy
Filed with ASX · · 9 pages · English
Summary by 6ix AI
This sensor is designed to operate at the Ultra Edge, processing data locally to enhance performance in various applications, including healthcare, sports, and defense. The company emphasizes that this technology is built on a proven platform that has been FDA-cleared and TGA-certified, ensuring its readiness for commercial deployment. Mathew Regan, CEO of dorsaVi, highlighted the sensor's capability to deliver immediate biofeedback, which is crucial for improving movement outcomes.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from dorsaVi
- dorsaVi Commences Tape-Out of Validation Chip
- dorsaVi Finalises RRAM-CMOS Validation Chip Design
- dorsaVi Well Funded Following $500k Options Exercise
- DorsaVi Limited (ASX: DVL) Licenses NTU Singapore Robotics IP to Accelerate Exoskeleton and Collaborative Robotics Strategy
- dorsaVi Licenses Human Robot Collaboration IP
Later from dorsaVi
- dorsaVi Commences Fabrication of First RRAM-CMOS Chip
- dorsaVi Completes CMOS Fabrication for RRAM Validation Chip
- DVL June 2026 Appendix 4E and Annual Report
- dorsaVi Characterises RRAM Energy Efficiency for Physical AI
- dorsaVi targets humanoid robotics with neuromorphic IP, RRAM
Follow dorsaVi into a list and get an email when it puts out news.
Follow dorsaVi